Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan
- PMID: 21702023
- PMCID: PMC3848710
- DOI: 10.1002/art.30514
Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan
Abstract
Eosinophilia-myalgia syndrome (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chronic neuropathy and skin induration. An epidemic of EMS in 1989 was linked to consumption of L-tryptophan that had originated from a single source. Following the ban by the Food and Drug Administration (FDA) on the sale of L-tryptophan, the incidence of EMS declined rapidly. Moreover, no new cases have been described since the FDA ban was lifted in 2005. We report the clinical, histopathologic, and immunogenetic features of a new case of L-tryptophan-associated EMS, along with evidence of activated transforming growth factor β and interleukin-4 signaling in the lesional skin.
Copyright © 2011 by the American College of Rheumatology.
Figures



References
-
- Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med. 1990;322:869–73. - PubMed
-
- Silver RM, Heyes MP, Maize JC, Quearry B, Vionnet-Fuasset M, Sternberg EM. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med. 1990;322:874–81. - PubMed
-
- Swygert LA, Back EE, Auerbach SB, Sewell LE, Falk H. Eosinophilia-myalgia syndrome: mortality data from the US national surveillance system. J Rheumatol. 1993;20:1711–17. - PubMed
-
- Eosinophilia-myalgia syndrome and L-tryptophan-containing products--New Mexico, Minnesota, Oregon, and New York, 1989. Centers for Disease Control (CDC) MMWR Morb Mortal Wkly Rep. 1989;38:785–8. - PubMed
-
- Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med. 1990;323:357–65. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01-HG-004499/HG/NHGRI NIH HHS/United States
- R01 AR042309/AR/NIAMS NIH HHS/United States
- U01 AR055063/AR/NIAMS NIH HHS/United States
- R56 AR042309/AR/NIAMS NIH HHS/United States
- R01 AR049025/AR/NIAMS NIH HHS/United States
- AR-42309/AR/NIAMS NIH HHS/United States
- U01-AR-055063/AR/NIAMS NIH HHS/United States
- R25-CA-134286/CA/NCI NIH HHS/United States
- Z01 ES101074/ImNIH/Intramural NIH HHS/United States
- Z01-ES-101074/ES/NIEHS NIH HHS/United States
- R25 CA134286/CA/NCI NIH HHS/United States
- R01-CA-077485/CA/NCI NIH HHS/United States
- R01 HG004499/HG/NHGRI NIH HHS/United States